Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes-Reference-Cited by-同舟云学术

Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn’s Disease: Patient Selection and Reported Outcomes

Published:2023-01 Issue: Volume:Volume 17 Page:273-282
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Horst Sara,Cross Raymond K

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference42 articles.

1. The Tale of IL-12 and IL-23: A Paradigm Shift

2. IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?

3. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting

4. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

5. IL-23 is essential for T cell–mediated colitis and promotes inflammation via IL-17 and IL-6

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases;Frontiers in Pharmacology;2024-09-06

2. Terápiás kihívások nehezen kezelhető, penetráló Crohn-betegségben – multidiszciplináris megoldás;Orvosi Hetilap;2024-08-11

3. Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review;Cureus;2024-07-25

4. New targeted pharmacotherapy and experimental therapies for inflammatory bowel disease;Journal of Integrative Medicine and Research;2024-07

5. Advancements in Targeted Therapies for the Management of Crohn’s Disease: A Comprehensive Review;Cureus;2024-06-05